Two Sigma Advisers LP Reduces Holdings in Novavax, Inc. (NASDAQ:NVAX)

Two Sigma Advisers LP cut its stake in Novavax, Inc. (NASDAQ:NVAX - Free Report) by 61.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 779,700 shares of the biopharmaceutical company's stock after selling 1,219,700 shares during the quarter. Two Sigma Advisers LP owned about 0.49% of Novavax worth $6,269,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of NVAX. Spire Wealth Management purchased a new position in Novavax in the fourth quarter valued at about $29,000. New Age Alpha Advisors LLC acquired a new stake in shares of Novavax during the fourth quarter worth about $35,000. KBC Group NV lifted its holdings in shares of Novavax by 97.0% during the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 3,917 shares during the period. TigerOak Management L.L.C. acquired a new stake in shares of Novavax during the fourth quarter worth about $86,000. Finally, AlphaQuest LLC lifted its holdings in shares of Novavax by 290.1% during the fourth quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 7,940 shares during the period. Hedge funds and other institutional investors own 53.04% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on NVAX. B. Riley reaffirmed a "buy" rating on shares of Novavax in a report on Monday, May 19th. BTIG Research assumed coverage on Novavax in a report on Friday, February 28th. They issued a "buy" rating and a $19.00 price target for the company. JPMorgan Chase & Co. decreased their price target on Novavax from $9.00 to $7.00 and set an "underweight" rating for the company in a report on Friday, May 9th. Finally, TD Cowen raised Novavax to a "hold" rating in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat, Novavax has a consensus rating of "Hold" and an average target price of $19.00.

Novavax Stock Down 1.5%

Shares of Novavax stock traded down $0.11 on Friday, reaching $7.09. The company's stock had a trading volume of 2,055,443 shares, compared to its average volume of 6,838,479. The company has a market capitalization of $1.15 billion, a P/E ratio of -3.13, a PEG ratio of 2.85 and a beta of 3.21. Novavax, Inc. has a 52-week low of $5.01 and a 52-week high of $23.86. The stock has a 50-day moving average price of $6.57 and a 200-day moving average price of $7.78.

Novavax (NASDAQ:NVAX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $2.93 EPS for the quarter, beating analysts' consensus estimates of $0.71 by $2.22. The business had revenue of $666.66 million during the quarter, compared to analysts' expectations of $204.08 million. The firm's quarterly revenue was up 610.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.05) earnings per share. Sell-side analysts forecast that Novavax, Inc. will post -1.46 earnings per share for the current fiscal year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.